⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Neurobiology and Treatment of Reading Disability in NF-1

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neurobiology and Treatment of Reading Disability in NF-1

Official Title: Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF-1)

Study ID: NCT00624234

Study Description

Brief Summary: The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs as children with idiopathic reading disabilities do, and to determine which intervention is best for particular learner profiles.

Detailed Description: The most common concern of parents of children with neurofibromatosis type 1 (NF-1) is learning disabilities (LD). Approximately one half of all children with NF-1 have LD-the most debilitating and common of which are reading disabilities. The purpose of this study is to determine if children with NF-1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs known to improve the decoding deficits in children with idiopathic reading disabilities. The trial will also determine which intervention is best for particular learner profiles. The overall purpose of this research is to gain a deeper understanding of the characteristics and treatment of reading disabilities in NF-1. In the trial, researchers will compare children with NF-1 who show weaknesses in reading to children with reading disabilities of no known cause (idiopathic) using two different interventions and behavioral and neurobiological measures. Both interventions focus on teaching sound-symbol relationships, but vary in terms of relative emphasis on verbal versus visual methods of teaching. Scientists hope findings from the trial will advance knowledge about the best therapies for LD in children with NF-1. And, by further refining how children with NF-1 who have reading disabilities are similar (or different) to children with idiopathic reading disabilities, the researchers may be able to learn if reading interventions that address areas other than decoding will also benefit children with NF-1. Also, by understanding the similarities and/or differences in the neuropsychological and neurobiological profiles of children with NF-1 who have reading disabilities, and those without, scientists will be able to refine the cognitive phenotype and neurobiological characteristics of NF-1, which will further understanding of central nervous system abnormalities in NF-1.

Eligibility

Minimum Age: 8 Years

Eligible Ages: CHILD

Sex: ALL

Healthy Volunteers: Yes

Locations

Vanderbilt University, Vanderbilt University Institute of Imaging Science, Nashville, Tennessee, United States

Contact Details

Name: Laurie E. Cutting, Ph.D.

Affiliation: Vanderbilt University Special Education Department

Role: PRINCIPAL_INVESTIGATOR

Name: Martha Bridge Denckla, M.D.

Affiliation: Kennedy Krieger Institute, Johns Hopkins University, Johns Hopkins University School of Medicine

Role: PRINCIPAL_INVESTIGATOR

Name: Sheryl L. Rimrodt, M.D.

Affiliation: Vanderbilt University Pediatrics Department

Role: PRINCIPAL_INVESTIGATOR

Name: John Gore, Ph.D.

Affiliation: Vanderbilt University

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: